2. 🗶

3. **X**

4. **X**

Name

Address

Country

City

Please type a plus sign (+) inside this box

PTO/SB/05 (08-00) Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. | MIT 7501 CON Campbell Rogers First Inventor MODULATION OF VASCULAR HEALING BY INHIBITION OF LEUKOCYTE ADHESION AND FUNCTION

EL 709 418 819 US Express Mail Label No. (Only for new nonprovisional applications under 37 CFR 1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: Box Patent Application Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or (Submit an original and a duplicate for fee processing) Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) Specification [Total Pages 28] Computer Readable Form (CRF) (preferred arrangement set forth below) - Descriptive title of the invention b. Specification Sequence Listing on: - Cross Reference to Related Applications i. ☐ CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, ii. 🗷 paper or a computer program listing appendix c. X Statements verifying identity of above copies - Background of the Invention Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) - Claim(s) Power of 37 CFR 3.73(b) Statement 10. 🗶 - Abstract of the Disclosure Attorney (when there is an assignee) English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) [Total Sheets 3] Copies of IDS Information Disclosure 12. X 5. Oath or Declaration [Total Pages 3] Citations Statement (IDS)/PTO-1449 Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) 13. 🗶 Preliminary Amendment X Return Receipt Postcard (MPEP 503) (for continuation/divisional with Box 17 completed) 14. **X** (Should be specifically itemized) **DELETION OF INVENTOR(S)** Certified Copy of Priority Document(s) (if foreign priority is claimed) 15. Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR Check for \$355.00 Other: 1.63(d)(2) and 1 33(b). Application Data Sheet. See 37 CFR 1.76 17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: 08 / 823,999 of prior application No. Continuation-in-part (CIP) Divisional ★ Continuation Examiner Gambel, P. Group / Art Unit __1644 Prior application information For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying confirmation or divisional application and is hereby incorporated by reference.

The incorporation can only be relied upon when a portion with the first part of the submitted application parts.

18. CDRH 354-06125 CE ADDRESS Customer Number or Bar Code Label Correspondence address below Patrea L. Pabst Arnall Golden & Gregory, LLP 2800 One Atlantic Center 1201 West Peachtree Street GA 30309-3450 Atlanta Zip Code State (404)873-8795 (404) 873-8794 **United States** Telephone Patrea L.Palost 31,284 Registration No. (Attorney/Agent) Name (Print/Type)

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231. MIT 7501 CON (BWH 0389)

20220/391

02/07/01

Ø

PTO/SB/17 (08-00)
Approved for use through 10/31/2002 OMB 0651-0032
U S. Patent and Trademark Office; U S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE	TRA	NSI	MIT.	TAL
	for F	Y 20	100	

Patent fees are subject to annual revision

	TOTAL	. AMOUNT	OF PAY	MENT
--	-------	----------	--------	------

(\$)355.00

Complete if Known				
Application Number	Continuation of 08/823,999			
Filing Date	February 7, 2001			
First Named Inventor	Campbell Rogers			
Examiner Name				
Group Art Unit				
Attorney Docket No.	MIT 7501 CON			

METHOD OF PAYMENT (check one)	FEE CALCULATION (continued)			
The Commissioner is hereby authorized to charge	3. ADDITIONAL FEES			
Deposit Of October 2015	Large Entity Small Entity Fee Fee Fee Fee Fee Fee Pee Pee Pee Pee	d		
Account Number 01-2507	Code (\$) Code (\$) 105 130 205 65 Surcharge - late filing fee or oath	$\exists 1$		
Account Name Arnall Golden & Gregory, LLP	127 50 227 25 Surcharge - late provisional filing fee or cover sheet			
Charge Any Additional Fee Required Under 37 CFR 1 16 and 1 17	139 130 139 130 Non-English specification			
Applicant claims small entity status	147 2,520 147 2,520 For filing a request for ex parte reexamination	_		
See 37 CFR 1 27 2. X Payment Enclosed:	112 920* 112 920* Requesting publication of SIR prior to Examiner action			
Credit card Money Order Other Other	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action			
FEE CALCULATION	115 110 215 55 Extension for reply within first month	_		
1. BASIC FILING FEE	116 390 216 195 Extension for reply within second month	_		
Large Entity Small Entity	117 890 217 445 Extension for reply within third month	_		
Fee Fee Fee Fee Description	118 1,390 218 695 Extension for reply within fourth month			
σοαε (ψ) σοαε (ψ)	128 1,890 228 945 Extension for reply within fifth month	\dashv		
101 710 201 355 Utility filing fee 355.00	119 310 219 155 Notice of Appeal			
107 490 207 245 Plant filing fee	120 310 220 155 Filing a brief in support of an appeal	\dashv		
108 710 208 355 Reissue filing fee	121 270 221 135 Request for oral hearing	\dashv		
114 150 214 75 Provisional filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding	\dashv		
	140 110 240 55 Petition to revive - unavoidable			
SUBTOTAL (1) (\$) 355.00	141 1,240 241 620 Petition to revive - unintentional	_		
2. EXTRA CLAIM FEES	142 1.240 242 620 Utility issue fee (or reissue)			
Fee from Extra Claims below Fee Paid				
Total Claims 17 - 20 = 0 X = 0	144 600 244 300 Plant issue fee			
Independent 2 - 3 = 0 X = 0	122 130 122 130 Petitions to the Commissioner			
Multiple Dependent	123 50 123 50 Petitions related to provisional applications			
Louis Entitle 9 . II E. 4%	126 240 126 240 Submission of Information Disclosure Stmt			
Large Entity Small Entity Fee Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)			
103 18 203 9 Claims in excess of 20 102 80 202 40 Independent claims in excess of 3	146 710 246 355 Filing a submission after final rejection (37 CFR § 1 129(a))	7		
104 270 204 135 Multiple dependent claims in excess of 3	149 710 249 355 For each additional invention to be examined (37 CFR § 1 129(b))			
109 80 209 40 ** Reissue independent claims	179 710 279 355 Request for Continued Examination (RCE)			
over original patent 110 18 210 9 ** Reissue claims in excess of 20	169 900 169 900 Request for expedited examination	\exists		
110 18 210 9 ** Reissue claims in excess of 20 and over onginal patent	of a design application	-		
	Other fee (specify)	닉		
SUBTOTAL (2) (\$) 0	Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)			
SUBMITTED BY	Complete (if applicable)			
Name (Print/Type) Patrea L. Pabst \	Registration No. 31,284 Telephone (404) 873-8794			
Signature	Date 7/2/2001			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Campbell Rogers, Elazer R. Edelman, and Daniel I. Simon

Serial No.: Continuation of 08/823,999 Express Mail Label No.: EL 709 418 819 US

Date of Deposit: February 7, 2001

Filed: February 7, 2001

For: MODULATION OF VASCULAR HEALING BY INHIBITION

OF LEUKOCYTE ADHESION AND FUNCTION

BOX PATENT APPLICATION Assistant Commissioner for Patents Washington, D.C. 20231

REQUEST FOR FILING A CONTINUATION APPLICATION UNDER 37 C.F.R. § 1.53(b)

Sir:

This is a request for filing a continuation application under 37 C.F.R. § 1.53(b), of copending prior application U.S.S.N. 08/823,999 filed March 25, 1997, entitled 'Modulation of Vascular Healing by Inhibition of Leukocyte Adhesion and Function", by Campbell Rogers, Elazer R. Edelman, and Daniel I. Simon. The application includes 1 page of abstract, 24 pages of specification, 3 pages of claims, 3 sheets of formal drawings, and a copy of the executed Declaration for Patent Application from prior application U.S.S.N. 08/823,999.

A Preliminary Amendment and an Information Disclosure Statement are enclosed.

Also enclosed from prior application U.S.S.N. 08/823,999 are copies of the (1) executed Assignment from Campbell Rogers and Elazer R. Edelman to Massachusetts Institute of Technology, recorded on May 27, 1997, at Reel 8640, Frame 0041; (2) executed Assignment from Daniel I. Simon to Brigham and Women's Hospital, Inc., recorded on May 27, 1997, at

Continuation of U.S.S.N. 08/823,999

Filed: February 7, 2001

REQUEST FOR FILING A CONTINUATION

APPLICATION UNDER 37 C.F.R. § 1.53(b) Express Mail Label No.: EL 709 418 819 US

Date of Deposit: February 7, 2001

Reel 8640, Frame 0123; (3) executed Certificate Under 37 C.F.R. § 3.73(b) by Massachusetts

Institute of Technology; and (4) executed Certificate Under 37 C.F.R. § 3.73(b) by Brigham and

Women's Hospital, Inc.

Pursuant to 37 C.F.R. § 1.63(d), the copy of the executed Declaration included in the

new application is a copy of the executed Declaration filed in parent application Serial

No. 08/823,999, to which the new application claims benefit.

This application contains nucleic acid and/or protein sequences as defined in 37 C.F.R.

§§ 1.821-1.825. The sequence listing for the new application is identical to the sequence listing

for the parent application Serial No. 08/823,999 filed March 25, 1997, by Campbell Rogers,

Elazer R. Edelman, and Daniel I. Simon. A sequence listing in computer readable form was

submitted May 24, 1999, in Application Serial No. 08/823,999 filed March 25, 1997.

No subsequent sequence listing was submitted.

Pursuant to 37 C.F.R. § 1.821(e), applicants hereby request that the computer readable

form of the sequence listing submitted in application Serial No. 08/823,999 be used as the

computer readable form of the sequence listing for the new application.

I declare that the material on the diskette is identical to the paper copy of the Sequence

Listing present in the above-identified parent application, and that all statements made on

information and belief are believed to be true and further that these statements were made with

the knowledge that willful false statements may jeopardize the validity of the application or any

patent issuing thereon.

2

1320641vI

MIT 7501 CON (BWH 0389) 20220/391 Continuation of U.S.S.N. 08/823,999

Filed: February 7, 2001

REQUEST FOR FILING A CONTINUATION APPLICATION UNDER 37 C.F.R. § 1.53(b)

Express Mail Label No.: EL 709 418 819 US

Date of Deposit: February 7, 2001

This application is entitled to small entity status pursuant to 37 C.F.R. § 1.27.

Submitted with the new application are a (1) check in the amount of \$355.00 to cover

the filing fee for a small entity; (2) Fee Transmittal (PTO/SB/17); and (3) Utility Patent

Application Transmittal (PTO/SB/45). It is believed that \$355.00 is the proper filing fee for a

small entity, as the application includes 2 independent claim and a total of 17 claims after entry

of the enclosed Preliminary Amendment.

The Commissioner is hereby authorized to charge any additional fees which may be

required, or credit any overpayment to Deposit Account No. 01-2507. To facilitate this process,

applicants have enclosed a duplicate of this letter.

The power of attorney in the prior application is to Patrea L. Pabst, Registration

No. 31,284.

This application is being filed on February 7, 2001, by mailing the application to Box

Patent Application, Assistant Commissioner of Patents, Washington, D.C. 20231 via the United

States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10.

The Express Mail Label Number appears in the heading of this paper which is attached to the

application papers pursuant to 37 C.F.R. § 1.10(b).

3

Continuation of U.S.S.N. 08/823,999

Filed: February 7, 2001

REQUEST FOR FILING A CONTINUATION APPLICATION UNDER 37 C.F.R. § 1.53(b)

Express Mail Label No.: EL 709 418 819 US

Date of Deposit: February 7, 2001

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq. ARNALL GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, GA 30309-3450

Respectfully submitted,

Patrea L. Pabst Reg. No. 31,284

Date: February 7, 2001

ARNALL, GOLDEN & GREGORY, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, Georgia 30309-3450 (404) 873-8794 (404) 873-8795 (fax)